openPR Logo
Press release

Synthetic siRNA Market Growth and Regional Forecast Upto 2024

08-10-2017 03:38 PM CET | Health & Medicine

Press release from: TMR - Research Reports

Synthetic siRNA Market Growth and Regional Forecast Upto 2024

Small interfering RNA or siRNA are a class of double-stranded RNA molecules, 20-25 base pairs in length. Synthetic siRNA’s are producedansfected into the cell either by polymer based transfection reagents, by cationic lipid or by electroporation i.e. physical delivery of siRNA through plasma membrane holes made by chemical modification or electrical field. siRNA are widely used to assess the individual contributions of genes to an assortment of cellular phenotypes like cell differentiation, insulin signaling, cytokinesis and apoptosis. Small interfering RNA is a powerful tool for modulating gene expression by RNA interference.

Read the Comprehensive Overview of Synthetic siRNA Market: http://www.transparencymarketresearch.com/synthetic-sirna-market.html

Synthetic siRNA Market: Dynamics

If compared to antibody-based drugs and small molecule drugs, the chief advantages of siRNA are the specificity determined by principles of complementary base pairing and ive due to rapid developments happening in whole-genome sequencing and molecular biology. Also, comprehensive nucleotide sequence databases have been established, including cDNA databases, disease gene databases, and human genomic databases laying a solid foundation for siRNA drug development. The basic strategy of a siRNA drug is to treat the disease by silencing the specific disease-promoting gene with wisely designed synthetic siRNA.path of clinical use. siRNA are unstable under physiological conditions. When siRNA traffics through the blood, it is easily digested by nucleases in the serum. Selecting appropriate siRNA is more complicated than choosing a code complementary to the sequence of the RNA to be silenced. This is because siRNA can sometimes silence multiple genes and its effects can often be unpredictable. In order to address this challenge, oinformatics tools to screen siRNA are developed by reagent vendors.

Synthetic siRNA Market: Segmentation

On the basis of tools and products used to release siRNA applications, the synthetic siRNA

Libraries
Software
Vectors

On the basis of therapeutic application, the synthetic siRNA market can be segmented into:

Oncology
Hepatitis
HIV infection

For synthetic siRNA experiments, controls are an essential part. There are three types of controls used in siRNA experiments, i.e. untreated control, negative control and positive control. The untreated control creates a useful baseline reference for gene expression and cell phenotypes levels. Negative controls help to separate sequence-specific effects from experimental conditions of cellular responses. The positive control ensures that the delivery method used is sufficient

Synthetic siRNA Market: Region-wise Outlook

Regionally, North America represents the largest market for synthetic siRNA followed by Europe. Europe is the second largest as well as the fastest growing market for synthetic siRNA. siRNA reagents are expected to constitute the largest area of RNAi application and synthesis of synthetic siRNA is anticipated to emerge as the fastest growing application field. The discovery of siRNA's has opened new avenues for therapeutic drug development. Many diseases caused by the inappropriate activity of specific genes and the ability to silence such genes selectively using synthetic siRNA’s

Request for the Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=25991

Synthetic siRNA Market: Key Players

The keyAmbion, B-Bridge, Bioneer, Dharmacon (ThermoFisher), Invitrogen, Integrated DNA Technologies, MWG Biotech, OligoEngine, Proligo (Sigma) and Qiagen.

About TMR

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Synthetic siRNA Market Growth and Regional Forecast Upto 2024 here

News-ID: 664736 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for RNA

Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand. Browse 156 Market Data Tables and 112 Figures spread through 175
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited. Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion. One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and